Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Wednesday

Praxis Precision Medicines (NASDAQ:PRAX) is projected to post its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Praxis Precision Medicines to post earnings of ($3.45) per share and revenue of $0.0590 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:00 AM ET.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its earnings results on Monday, August 4th. The company reported ($3.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.40) by $0.09. On average, analysts expect Praxis Precision Medicines to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Praxis Precision Medicines Price Performance

Shares of PRAX opened at $199.33 on Wednesday. The company has a market capitalization of $4.22 billion, a PE ratio of -16.22 and a beta of 2.62. Praxis Precision Medicines has a one year low of $26.70 and a one year high of $205.89. The company’s fifty day moving average price is $71.97 and its 200 day moving average price is $53.44.

Institutional Trading of Praxis Precision Medicines

A number of hedge funds have recently modified their holdings of PRAX. Tower Research Capital LLC TRC grew its holdings in shares of Praxis Precision Medicines by 24.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company’s stock worth $77,000 after purchasing an additional 359 shares in the last quarter. Exome Asset Management LLC bought a new position in Praxis Precision Medicines in the second quarter worth $2,481,000. Brevan Howard Capital Management LP acquired a new stake in Praxis Precision Medicines during the second quarter worth $358,000. Adage Capital Partners GP L.L.C. boosted its stake in Praxis Precision Medicines by 13.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,974,585 shares of the company’s stock worth $83,031,000 after buying an additional 231,827 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Praxis Precision Medicines by 103.9% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,873 shares of the company’s stock valued at $1,005,000 after buying an additional 12,165 shares during the period. Institutional investors own 67.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Guggenheim set a $350.00 price target on Praxis Precision Medicines and gave the company a “buy” rating in a research report on Thursday, October 16th. Oppenheimer increased their target price on Praxis Precision Medicines from $97.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Lifesci Capital raised Praxis Precision Medicines to a “strong-buy” rating in a research report on Wednesday, September 3rd. Needham & Company LLC upped their price target on Praxis Precision Medicines from $80.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $300.00 price objective (up previously from $65.00) on shares of Praxis Precision Medicines in a research note on Thursday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Praxis Precision Medicines currently has a consensus rating of “Moderate Buy” and an average target price of $222.36.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.